Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, placebo-controlled trial of PRAX-562 in patients with rare adult cephalgias

Next Previous
Trial Profile

A Phase 2, placebo-controlled trial of PRAX-562 in patients with rare adult cephalgias

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relutrigine (Primary)
  • Indications Headache disorders
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 09 May 2022 Status changed from planning to discontinued, according to a Praxis Precision Medicines media release.
  • 09 May 2022 According to a Praxis Precision Medicines media release, as a result of company's strategic decision to renew its focus toward epilepsy indications, the company has discontinued this study.
  • 18 Jan 2022 According to a Praxis Precision Medicines media release, this trial is expected to begin in the first quarter of 2022,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top